

Article

Interaction of Human Serum Album and C₆₀ Aggregates in Solution

Maoyong Song, Shufang Liu, Junfa Yin and Hailin Wang *

State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 10085, China;

E-Mails: smsong@rcees.ac.cn (M.S.); liushufang405@163.com (S.L.); jfyin@rcees.ac.cn (J.Y.)

* Author to Whom correspondence should be addressed; E-Mail: hlwang@rcees.ac.cn;
Tel./Fax: +0086-10-62849600.

Received: 30 March 2011; in revised form: 12 July 2011 / Accepted: 27 July 2011 /

Published: 4 August 2011

Abstract: An important property of C₆₀ in aquatic ecotoxicology is that it can form stable aggregates with nanoscale dimensions, namely nC₆₀. Aggregation allows fullerenes to remain suspended for a long time, and the reactivity of individual C₆₀ is substantially altered in this aggregate form. Herein, we investigated the interaction of nC₆₀ and human serum albumin (HSA) using the methods of fluorescence, fluorescence dynamics, circular dichroism (CD), and site marker competitive experiments. We proposed a binding model consistent with the available experimental results for the interactions of nC₆₀ with HSA. During the interaction process, the structure and conformation of HSA were affected, leading to functional changes of drug binding sites of HSA.

Keywords: nC₆₀; HSA; interaction; protein; fluorescence

1. Introduction

Since the discovery of fullerene (C₆₀) in 1985 [1], concerns have been raised about the proposed applications of C₆₀ and its derivatives in biology and pharmacology [2,3]. These potential applications include items as varied as antiviral, anticancer, or antioxidant agents [4], and drug delivery vehicles [5,6]. Despite the broad range of research focused on the application potential of fullerenes, their toxicological and environmental effects are still not well known [7]. With an octanol-water

partition coefficient $\log K_{OW}$ of 6.67 and a solubility of less than 10^{-9} mg/L, pristine fullerene is poorly soluble in water [8]. For C_{60} fullerene, its interaction with proteins has been poorly studied due in particular to its low solubility in water, and hence much research has focused on the interactions between its water-soluble derivatives and some proteins such as HIV protease [9,10], a fullerene-specific antibody [11], human serum albumin (HSA) [12] and bovine serum albumin (BSA) [13].

An important property of C_{60} in aquatic ecotoxicology is its acquisition of charge and ability to form relatively stable clusters (referred to as nC_{60}) in aqueous systems, by means of natural processes like water flow and mixing, as well as by vigorous stirring in the laboratory [14–16]. Aggregation allows fullerenes to remain suspended for weeks or months [17], this aspect of nC_{60} may provide a more complete understanding of how it will behave in natural systems or in organisms.


In previous work, BSA was found to adopt a more flexible conformational state on the boundary surface of gold nanoparticles as a result of the conformational changes in the bioconjugates [18]. It was also demonstrated that C_{60} nanoparticles can be stabilized by nonspecific adsorption of HSA and remain well dispersed even in the physiological environment [19]. Therefore, for further understanding of the transportation of nC_{60} fullerene in the bodies and the resulting related bio-effects, the interaction of nC_{60} fullerene with proteins is crucial and must be ascertained. In this study, the interaction between human serum albumin and nC_{60} in aqueous solution was investigated by fluorescence, fluorescence dynamics, circular dichroism (CD), and binding site marker competitive experiments.

2. Results and Discussion

2.1 The Fluorescence Quenching of HSA by nC_{60}

Quenching refers to any process which decreases the fluorescence intensity of a given substance. A variety of processes can result in quenching, such as excited state reactions, energy transfer, complex-formation and collisional quenching. Figure 1 shows the fluorescence spectra of HSA in the absence and the presence of nC_{60} in phosphate buffer with an excitation wavelength of 280 nm. HSA displayed the maximum emission at a wavelength of 343 nm. The fluorescence intensity of HSA decreased with increasing concentration of nC_{60} and the maximum emission wavelength was slightly red shifted. It is known that the shift of maximum emission wavelength corresponded to a polarity change around the chromophore residues. Red shift indicates that the microenvironment of fluorophors in HSA is changed after addition of nC_{60} .

Figure 1. Fluorescence spectra of human serum albumin (HSA) in the presence of nC₆₀ aggregates. HSA concentration was 20 μM. The concentration of C₆₀ (from A to F) was 0, 1.41, 2.83, 5.66, 8.48, and 11.30 μM, respectively (pH = 7.4; ex = 280 nm).




2.2. Quenching Mechanism of nC₆₀ to HSA

For dynamic quenching, the quenching is an additional process that deactivates the excited state besides radiative emission through the collision between the quencher and fluorophore. As for HSA, the dependence of the emission intensity on quencher concentration $[Q]$ is given by the Stern-Volmer equation:

$$F_0 / F = 1 + K_q \tau_0 [Q] = 1 + K_{sv} [Q] \quad (1)$$

where F and F_0 are the fluorescence intensity in the absence and in the presence of quencher, respectively; τ_0 is the lifetime of HSA; K_q is the bimolecular rate constant for the dynamic reaction of the quencher with the fluorophore; K_{sv} is called the Stern-Volmer constant.

For static quenching, the binding of a quencher (Q) to a protein (M) can be described with the following reaction:



Then the binding constant (K) is given by

$$K = \frac{[MQ_n]}{[M][Q]^n} \quad (2)$$

The relation between the fluorescence intensity and concentration of quencher $[Q]$ is given by

$$[M]_0 = [M] + [MQ_n] \quad (3)$$

$$\frac{F_0 - F}{F} = \frac{[M]_0 - [M]}{[M]} = \frac{[MQ_n]}{[M]} = K[Q]^n \quad (4)$$

Rearrange Equation (4)

$$\frac{F_0}{F} = 1 + K[Q]^n \quad (5)$$

The quenching data were presented as a plot of $\frac{F_0}{F}$ versus $[Q]$, and the Stern-Volmer plot is an upward curvature, concave towards the y-axis, as shown in Figure 2A.

This result indicates that HSA can be quenched both by collisions and by complex formation with C_{60} nanoparticles. Then the fractional fluorescence remaining ($\frac{F_0}{F}$) is given by

$$\frac{F}{F_0} = f(1 + K_{sv}[Q]) \quad (6)$$


where f is the fraction not complexed, and $(1 + K_{sv}[Q])$ is the fraction not quenched by collisional encounters.

According to the definition, f can be obtained from Equation (5), and then rearrangement of Equation (6) yields:

$$\left(\frac{F_0}{F} - 1\right) = K_{sv}[Q] + K[Q]^n + K_{sv}K[Q]^{n+1} \quad (7)$$

The nonlinear fitting analysis was performed by plotting $\left(\frac{F_0}{F} - 1\right)$ against Q (Figure 2B). From the Stern-Volmer plot, the value of K_{sv} was $6.56 \times 10^4 \text{ L}\cdot\text{mol}^{-1}$. The K_q was easily calculated according to Equation (1), $6.56 \times 10^{12} \text{ L}\cdot\text{mol}^{-1}\cdot\text{s}^{-1}$, which is much higher than the maximal collided dynamic quenching constant ($2.0 \times 10^{10} \text{ L}\cdot\text{mol}^{-1}\cdot\text{s}^{-1}$) [20]. This result indicates that the fluorescence quenching of HSA by the addition of nC_{60} is mainly caused by static quenching. There is non-linearity obtained from Stern-Volmer when the nC_{60} concentration is lower than $11.30 \mu\text{M}$. When nC_{60} concentration is higher than $11.30 \mu\text{M}$, the intrinsic fluorescence of HSA is significantly quenched. The plot appears to be an upward curvature with increasing nC_{60} concentration, which is a characteristic feature of mixed quenching. This suggests that it is not a single quenching mechanism that exists in the binding process. The mechanism of HSA quenching caused by water-soluble pristine nC_{60} is different to that caused by water-soluble nC_{60} derivative [12].


Figure 2. (A) The Stern-Volmer plot for the fluorescence quenching of HSA by nC_{60} ; (B) Nonlinear fitting analysis performed by plotting $(F_0/F-1)$ against $[Q]$.



2.3. The Conformation Study of HSA


Synchronous fluorescence spectroscopy is a common method used to provide information about conformational changes of protein since the possible shift of maximum emission wavelength is related to the polarity of the environment. The synchronous fluorescence spectra of HSA-nC₆₀ system are shown in Figure 3. The maximum emission wavelength of tyrosine residues has a small red shift (from 283 nm to 285 nm) when $\Delta\lambda = 15$ nm, indicating that there are some changes in the environment of the tyrosine residues. The maximum emission wavelength of tryptophan residues red shifts from 279.5 nm to 281.5 nm when $\Delta\lambda = 60$ nm (Figure 3B). This suggests that there is a less hydrophobic or more polar environment change around the tyrosine residues and tryptophan residues. This may be ascribed to the fact that the hydrophobic amino acid structure surrounding tryptophan residues in HSA tends to collapse slightly, resulting in tyrosine residues and tryptophan residues being more exposed to the aqueous phase.

Figure 3. Synchronous fluorescence spectra of HSA in the presence of nC₆₀. (A) $\Delta\lambda = 15$ nm; (B) $\Delta\lambda = 60$ nm. HSA concentration is 20 μ M. The concentration of C₆₀ (from A to F) was 0, 1.41, 2.83, 5.66, 8.48, 11.30 μ M, respectively.



Circular dichroism spectra can sensitively monitor conformation changes in the protein upon interaction with the ligand. In this experiment, the calculated α -helicity content of native HSA solution is 54.9%, and with the addition of nC₆₀ to the native HSA solution, the α -helicity content of HSA increased to 59.8%, 61.2% and 62.0% (Figure 4). Apparently, the higher the added nC₆₀ concentration, the more the α -helicity content. The increase of α -helicity content indicated that the binding of HSA and nC₆₀ induces protein folding, which results in some hydrophobic regions becoming more compact.


Figure 4. The circular dichroism (CD) spectra of the HSA-nC₆₀ system. Concentration of HSA was 7.3 μM; Concentration of nC₆₀ (from A to D) was 0, 3.38, 5.63, 11.8 μM, respectively.



2.4. Interaction between HSA and nC₆₀

It is well known that HSA has two major drug binding sites, site I and site II, which are located in the hydrophobic pocket of sub-domain IIA and sub-domain IIIA, respectively. In order to identify the nC₆₀-binding site on HSA, two probes were used. One probe of HSA is dansylamide (DNSA), whose binding site is located in the region of sub-domain IIA (sudlow site I); another probe, dansylproline (DP) is bound to HSA in the sub-domain IIIA (sudlow site II) [21,22]. During the experiment, nC₆₀ was gradually added to the solution of HSA with site probes held in equimolar concentrations (20 μM). No absorption of these two probes to nanoparticles of C₆₀ was observed in capillary electrophoresis analysis (data not shown). As shown in Figure 5, only the probes or HSA alone have no fluorescence signal within the wavelengths 400–600 nm. When the probes and HSA are mixed together, the DNSA-HSA complex has a maximum emission wavelength at 487 nm (excitation wavelength 350 nm) and DP-HSA has a maximum emission wavelength at 480 nm (excitation wavelength 375 nm). With the addition of nC₆₀ to the HSA-probe solution, the fluorescence intensity of the HSA-probe complex was significantly lower than that without nC₆₀, indicating that the binding of DNSA/DP to HSA was affected by adding nC₆₀. The fluorescence intensity of DNSA-HSA was lower than that of DP-HSA, indicating that nC₆₀ could more strongly influence the binding of DNSA to HSA than that of NP to HSA.

Figure 5. Effect of nC_{60} on binding site probe-HSA system. Concentrations of HSA and probes (DNSA and DP) were 20 μM . (a) 1: HSA only; 2: DNSA only; Ex = 350 nm; (b) 1: HSA only, 2: DP only; ex = 375 nm. Concentrations of C_{60} (from 3 to 8) were 0, 1.41, 2.83, 5.66, 8.48, 11.30 μM , respectively. The inserts correspond to the molecular structure of binding site probes.




2.5. Representation of Interaction of HSA and nC_{60}

Our results above indicate that the fluorescence quenching and conformational changes of HSA can be attributed to the interaction between HSA and nC_{60} . C_{60} fullerene has also been reported to be bound to the subdomain IIA of HSA using time-resolved fluorescence decay experiments, docking calculations, and binding site alignment methods [13,23]. Here we have employed several approaches in order to address the issue of fullerene interactions with proteins. What needs to be especially pointed out is that it is difficult to incorporate nC_{60} into the binding pocket because the size of nC_{60} is larger than protein molecules. The hydrodynamic diameter of the nC_{60} nanoparticles was determined to be from 50 nm to 110 nm by TEM and DLS, respectively (Figure 6A,B). Ganazzoli *et al.* reported

atomistic computer simulations of some albumin subdomains on a hydrophobic graphite surface [24]. According to these simulations, we proposed a binding model to describe the interaction between HSA and nC₆₀ (Figure 6C). In this model, HSA is adsorbed on the surface of nC₆₀ aggregate which leads to the fluorescence quenching and conformational changes of HSA. The interaction sites were presumed to be near to Site I and Site II of HSA; following the structure and conformation of HSA was affected during adsorption. In our previous study, we have observed that HSA could compete for the surface of nC₆₀ with functional enzymes [25].

Figure 6. (A) Transmission electron microscopy (TEM) image of nC₆₀; (B) The mean hydrodynamic diameter of the nC₆₀ measured by dynamic light scattering (DLS); (C) Schematic representation of HSA interacting with aggregate nC₆₀ surface.



3. Experimental

3.1. Materials

C₆₀ (99.5% purity) was obtained from Sigma Chemical Company, St. Louis, USA. HSA (98% purity, essentially fatty acid and globulin free) was purchased from NEB (USA). All solutions were prepared in ultrapure water with the resistivity of 18.2 MΩ·cm (ALGA system, UK). Phosphate buffer (10 mM, pH = 7.4) was prepared with chemicals of analytical pure grade, obtained from commercial sources, and filtered with a 0.22-μm filter (Millipore, Bedford, MA, USA). All other materials were of analytical pure grade.

3.2. Preparation and Characterization of Water-Soluble nC₆₀

C₆₀ suspensions were prepared according to the method described previously [26]. Ten milligrams of C₆₀ was completely dissolved in 10 mL toluene. Then 2.5 mL C₆₀ toluene solution was added into 50 mL water. After ultrasonic treatment for approximately 4 h, toluene was allowed to evaporate under vacuum for at least 1 h. The mean hydrodynamic diameter of the nC₆₀ nanoparticles was determined by transmission electron microscopy (TEM) and dynamic light scattering (DLS) (BI-200SM laser light scattering spectrometer, Brookhaven, USA).

3.3. Methods

Absorption spectra were recorded on a UV-2102PCS UV-Vis spectrophotometer (UNICO, USA) equipped with a 1.0 cm quartz cuvette at room temperature. The wavelength range was recorded from 200 to 500 nm.

All fluorescence emission spectra were recorded in the range of 300–450 nm on a LS-55 spectrofluorimeter (PE, USA) equipped with 100 μ L quartz cells. The bandwidth of excitation and emission (3 nm) and scan speed (300 nm/min) were kept constant within each data set. Fluorescence intensity at 343 nm was used for calculation in Stern-Volmer equation. All measurements were performed at room temperature (~25 °C).

Binding site marker competitive experiments were carried out by the fluorescence titration methods. The concentration of HSA and dansylamide/dansylproline (DNSA/DP) were all kept at 10 μ M. Then nC₆₀ was gradually titrated into the HSA-DNSA/DP systems. Fluorescence spectra were recorded with an excitation wavelength of 370 nm (for DNSA) and 375 nm (for DNP) in the range of 400–600 nm.

Circular dichroism (CD) spectroscopy was performed on a J-810 spectropolarimeter (Jasco Co., Japan) over a wavelength of 200–260 nm. The scanning speed was set at 500 nm/min. Each spectrum was the average of three successive scans and appropriate buffer solutions running under the same conditions were taken as blank and their contributions were subtracted from the experimental spectra.

4. Conclusions

We observed a quenching of fluorescence of HSA in the presence of nC₆₀, and fluorescence quenching mechanism was investigated by the Stern-Volmer equation which showed a characteristic feature for the combined fluorescence quenching. The binding of HSA to nC₆₀ increases the polar environment of the Trp residue, resulting in a red shift in the fluorescence spectra. The CD results showed that the percentage of α -helicity of HSA increased, revealing that the protein becomes more compact upon association with nC₆₀. The results indicate that the fluorescence quenching and conformational changes of HSA can be attributed to the interaction between HSA and nC₆₀. In the binding site marker competitive experiment, the binding of DNSA/DP to HSA was affected by adding nC₆₀. We propose that HSA interacted with aggregate nC₆₀ surface, and led to the functional changes of drug binding sites of HSA.

Acknowledgements

This research was supported by grants from the National Natural Science Foundation of China (Nos. 21077116, 20921063, 20890112, 20805057), and the National Basic Research Program of China (Nos. 09CB421605, 10CB933502) to M. Song and H. Wang.

References

1. Kroto, H.W.; Heath, J.R.; O'Brien, S.C.; Curl, R.F.; Smalley, R.E. C₆₀-Buckminsterfullerene. *Nature* **1985**, *318*, 162–163.
2. Wilson, L.J. Medical applications of fullerenes and metallofullerenes. *Electrochem. Soc. Interface* **1999**, *8*, 24–28.
3. Da Ros, T.; Prato, M. Medicinal chemistry with fullerenes and fullerene derivatives. *Chem. Commun.* **1999**, *8*, 663–669.
4. Bakry, R.; Vallant, R.M.; Najam-ul-Haq, M.; Rainer, M.; Szabo, Z.; Huck, C.W.; Bonn, G.K. Medicinal applications of fullerenes. *Int. J. Nanomed.* **2007**, *2*, 639–649.
5. Ashcroft, J.M.; Tsyboulski, D.A.; Hartman, K.B.; Zakharian, T.Y.; Marks, J.W.; Weisman, R.B.; Rosenblum, M.G.; Wilson, L.J. Fullerene (C₆₀) immunoconjugates: Interaction of water-soluble C₆₀ derivatives with the murine anti-gp240 melanoma antibody. *Chem. Commun.* **2006**, *28*, 3004–3006.
6. Zakharian, T.Y.; Seryshev, A.; Sitharaman, B.; Gilbert, B.E.; Knight, V.; Wilson, L.J. A fullerene-paclitaxel chemotherapeutic: Synthesis, characterization, and study of biological activity in tissue culture. *J. Am. Chem. Soc.* **2005**, *127*, 12508–12509.
7. Jia, G.; Wang, H.; Yan, L.; Wang, X.; Pei, R.; Yan, T.; Zhao, Y.; Guo, X. Cytotoxicity of carbon nanomaterials: Single-wall nanotube, multi-wall nanotube and fullerene. *Environ. Sci. Technol.* **2005**, *39*, 1378–1383.
8. Heymann, D. Solubility of fullerenes C₆₀ and C₇₀ in seven normal alcohols and their deduced solubility in water. *Fullerene Sci. Technol.* **1996**, *4*, 509–515.
9. Friedman, S.H.; DeCamp, D.L.; Sijbesma, R.; Srdanov, G.; Wudl, F.; Kenyon, G.L. Inhibition of the HIV-1 protease by fullerene derivatives: Model building studies and experimental verification. *J. Am. Chem. Soc.* **1993**, *115*, 6506–6509.
10. Marcorin, G.L.; Da Ros, T.; Castellano, S.; Stefancich, G.; Bonin, I.; Miertus, S.; Prato, M. Design and synthesis of novel [60]fullerene derivatives as potential HIV aspartic protease inhibitors. *Org. Lett.* **2000**, *2*, 3955–3958.
11. Braden, B.C.; Goldbaum, F.A.; Chen, B.X.; Kirschner, A.N.; Wilson, S.R.; Erlanger, B.F. X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: Biomolecular recognition of C(60). *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 12193–12197.
12. Zhang, X.F.; Shu, C.Y.; Xie, L.; Wang, C.R.; Zhang, Y.Z.; Xiang, J.F.; Li, L.; Tang, Y.L. protein conformation changes induced by a novel organophosphate-containing water-soluble derivative of a C₆₀ fullerene nanoparticle. *J. Phys. Chem. C* **2007**, *111*, 14327–14333.

13. Belgorodsky, B.; Fadeev, L.; Ittah, V.; Benyamini, H.; Zelner, S.; Huppert, D.; Kotlyar, A.B.; Gozin, M. Formation and characterization of stable human serum albumin-tris-malonic acid [C₆₀]fullerene complex. *Bioconjug. Chem.* **2005**, *16*, 1058–1062.
14. Brant, J.; Lecoanet, H.; Wiesner, M.R. Aggregation and deposition characteristics of fullerene nanoparticles in aqueous systems. *J. Nanopart. Res.* **2005**, *7*, 545–553.
15. Scharff, P.; Risch, K.; Carta-Abelmann, L.; Dmytruk, I.M.; Bilyi, M.M.; Golub, O.A.; Khavryuchenko, A.V.; Buzaneva, E.V.; Aksenov, V.L.; Avdeev, M.V.; *et al.* Structure of C₆₀ fullerene in water: Spectroscopic data. *Carbon* **2004**, *42*, 1203–1206.
16. Chen, X.; Kan, A.T.; Tomson, M.B. Naphtalene adsorption and desorption from aqueous C₆₀ fullerene. *J. Chem. Eng. Data* **2004**, *49*, 675–683.
17. Deguchi, S.; Alargova, R.G.; Tsuji, K. Stable dispersions of fullerenes C₆₀ and C₇₀ in water. Preparation and characterization. *Langmuir* **2001**, *17*, 6013–1017.
18. Shang, L.; Wang, Y.; Jiang, J.; Dong, S. pH-dependent protein conformational changes in albumin: gold nanoparticle bioconjugates: A spectroscopic study. *Langmuir* **2007**, *23*, 2714–2721.
19. Deguchi, S.; Yamazaki, T.; Mukai, S.; Usami, R.; Horikoshi, K. Stabilization of C₆₀ nanoparticles by protein adsorption and its implications for toxicity studies. *Chem. Res. Toxicol.* **2007**, *20*, 854–858.
20. Lakowicz, J.R.; Weber, G. Quenching of fluorescence by oxygen. Probe for structural fluctuations in macromolecules. *Biochemistry* **1973**, *21*, 4161–4170.
21. Sudlow, G.; Birkett, D.J.; Wade, D.N. The Characterization of two specific drug binding sites on human serum albumin. *Mol. Pharmacol.* **1975**, *11*, 824–832.
22. Chuang, V.T.; Kuniyasu, A.; Nakayama, H.; Matsushita, Y.; Hirono, S.; Otagiri, M. Helix 6 of subdomain III A of human serum albumin is the region primarily photolabeled by ketoprofen, an arylpropionic acid NSAID containing a benzophenone moiety. *Biochim. Biophys. Acta* **1999**, *1434*, 18–30.
23. Benyamini, H.; Shulman-Peleg, A.; Wolfson, H.J.; Belgorodsky, B.; Fadeev, L.; Gozin, M. Interaction of C₆₀-Fullerene and Carboxyfullerene with proteins: Docking and binding site alignment. *Bioconjug. Chem.* **2006**, *17*, 378–386.
24. Raffaini, G.; Ganazzoli, F. Simulation study of the interaction of some albumin subdomains with a flat graphite surface. *Langmuir* **2003**, *19*, 3403–3412.
25. Song, M.; Jiang, G.; Yin, J.; Wang, H. Inhibition of Taq polymerase activity by pristine fullerene nanoparticles can be mitigated by abundant proteins. *Chem. Commun.* **2010**, *46*, 1404–1406
26. Andrievsky, G.V.; Kosevich, M.V.; Vovk, O.M.; Shelkovsky, V.S.; Vashchenko, L.A. On the production of an aqueous colloidal solution of fullerenes. *J. Chem. Soc. Chem. Commun.* **1995**, 1281–1282.